Ocuphire Pharma, Inc.


1.69 (USD) • At close May 17, 2024
Bedrijfsnaam Ocuphire Pharma, Inc.
Symbool OCUP
Munteenheid USD
Prijs 1.685
Beurswaarde 43,682,277
Dividendpercentage 0%
52-weken bereik 1.5 - 4.58
Industrie Biotechnology
Sector Healthcare
CEO Mr. Richard J. Rodgers M.B.A.
Website https://www.ocuphire.com

An error occurred while fetching data.

Over Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light

Vergelijkbare Aandelen

Neoleukin Therapeutics, Inc. logo

Neoleukin Therapeutics, Inc.


3.49 USD

Zynerba Pharmaceuticals, Inc. logo

Zynerba Pharmaceuticals, Inc.


1.3 USD

Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc.


9.54 USD

IN8bio, Inc. logo

IN8bio, Inc.


1.03 USD

Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.


1.59 USD

Acasti Pharma Inc. logo

Acasti Pharma Inc.


2.69 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)